ClinicalTrials.gg
RecruitingNCT06059222OPTIMISTUpdated Jul 2, 2026

The Optimised Use of Romozosumab Study

A Phase 4 interventional study of Romosozumab and Zoledronate in Osteoporosis, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Planned enrollment
4th of 20
270 · median 80
Started
2023
with 2 others
Phase 4
10 of 20
5 open now
Registered
14th of 20
by date

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 10 in phase 4, and was the 14th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in standard doses (210 mg monthly (sc) and 5 mg yearly (iv), respectively).

The study will investigate if it is possible to maximize the effect of romosozumab by giving it in 2 periods of 6 months interrupted by zoledronate for 12 months compared to romosozumab for 12 months uninterrupted followed by zoledronate for 12 months. The investigators will also evaluate if 6 months of romosozumab followed by 18 months of zoledronate is non-inferior to the standard regimen of romosozumab for 12 months followed by zoledronate for 12 months.

Read the detailed description

Recent clinical trials have demonstrated the benefit of bone anabolic treatment over no treatment or antiresorptive treatment in terms of increasing bone mineral density (BMD) and reducing fracture risk for patients with osteoporosis. However, the bone anabolic treatment is expensive and therefore restricted to a limited group of patients.

This study is based on the hypothesis that treatment with romosozumab for 6 months, zoledronate for 12 months, and romosozumab for 6 months results in larger gains in bone mineral density than treatment regimens based on romosozumab treatment for 6 or 12 months followed by zoledronate for a total of 24 months of treatment due to reappearance of the bone anabolic effect of romosozumab upon retreatment.

The OPTIMIST study is a two-year, randomised, active controlled, open-label, intervention trial. The study includes 270 postmenopausal women who will be randomised to 3 groups. Group 1 (n=90) will receive romosozumab for 12 months followed by zoledronate for 12 months. Group 2 (n=90) will receive romosozumab for 6 months followed by zoledronate for 12 months and romosozumab for 6 months. Group 3 (n=90 ) will receive romosozumab for 6 months followed by zoledronate for 18 months.

The investigational drugs in this study are romosozumab 210 mg/2,34 mL and zoledronate 5 mg/100 mL

This study will include 270 treatment naïve postmenopausal women. When inclusion and exclusion criteria have been reviewed, and the participant meets the requirements for study participation and continues to participate in the study, the patients will be randomized 1:1:1 Data will be registered in RedCAP (eCRF) and site monitoring assessed by the local Good Clinical Practice unit (GCP-unit).

The patients will be recruited from the outpatient clinics and the Dual-Energy X-ray Absorptiometry (DXA) units to which patients are referred from their general practitioner or fracture liaison services (FLS) at:

Department of Endocrinology, Odense University Hospital Department of Endocrinology and Internal Medicine, Aarhus University Hospital Department of Endocrinology, Køge Hospital Department of Endocrinology, Hvidovre Hospital Department of Endocrinology, Bispebjerg Hospital

During the intervention phase, there will be obtained fasting blood test, high-resolution peripheral quantitative computed tomography (HR-pQCT),Oral Glucose Tolerance Test (OGTT), DXA, Vertebral fracture assessment (VFA) and biochemistry at different time stamps. From 105 patients there will be obtained bone marrow aspirates and performed jamshidi bone biopsies.

The study will therefore show if it would be possible to treat twice as many patients for the same prize but also if the treatment for 12 months can be optimized. The knowledge about the optimal use of romosozumab will be included in an update of osteoporosis treatment guidelines. This will lead to optimized treatment of patients with severe osteoporosis.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (postmenopausal for at least two years)
  • BMD T-score \< -2.5 at lumbar spine, total hip, or femoral neck
  • Osteoporotic fracture within the last 3 years at the spine, hip, pelvis, humerus or forearm after the age of 50 years.

Exclusion criteria

Exclusion Criteria:

  • Osteoporosis treatment including hormone replacement therapy within the last 5 years
  • Metabolic bone disease
  • Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, liver dysfunction (baseline phosphatase higher than twice upper limit), rheumatism, severe (chronic obstructive pulmonary disease), hypopituitarism, Cushing's disease
  • Ongoing treatment with (systemic)
  • Estimated (eGFR) \< 35 mL/min
  • for zoledronate according to the Supplementary protection certificates (SPC)
  • Contraindications for romosozumab according to the SPC
  • For the subgroup with Jamshidi contraindications for local anaesthetics according to the SPC
  • For the subgroup with Jamshidi biopsies contraindications for tetracycline or doxycykline according to the SPC
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Active comparator
    Group 1 - ROMO 12 months, ZOL 12 months

    90 patients 12 months of romosozumab (ROMO) followed by 12 months of zoledronate (ZOL)

    Drug: Romosozumab · Drug: Zoledronate

  • Active comparator
    Group 2 - ROMO 6 months, ZOL 12 months, ROMO 6 months

    90 patients 6 months of romosozumab followed by 12 months of zoledronate and lastly 6 months of romosozumab.

    Drug: Romosozumab · Drug: Zoledronate

  • Active comparator
    Group 3 - ROMO 6 months, ZOL 18 months

    90 patients 6 months of romosozumab followed by 18 months of zoledronate .

    Drug: Romosozumab · Drug: Zoledronate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in total hip BMD

    Change in total hip BMD

    Time frame: 24 months

Secondary outcomes

  1. Changes in femoral neck BMD

    Change in femoral neck BMD

    Time frame: 24 months

  2. Changes in trabecular bone volume fraction (bone volume/tissue volume, BV/TV) and cortical porosity measured by high-resolution peripheral quantitative computed tomography (HR-pQCT)

    Mean percent change in trabecular bone volume fraction and cortical porosity measured by HR-pQCT at the radius and tibia

    Time frame: 24 months

  3. Change in spine BMD

    Change in spine BMD

    Time frame: 24 months

Other outcomes

  1. Bone resorption and formation -Changes in P1NP (procollagen type I N-terminal propeptide)

    Changes in P1NP (blood sample)

    Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months

  2. Bone resorption and formation - Changes in CTX

    Changes in cross-linked C-terminal telopeptide (CTX) (blood sample)

    Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months

  3. Bone resorption and formation - Changes in collagen

    Bone turnover marker (BTM) collagen (blood sample)

    Time frame: 1, 3, 6, 12, 18, 19, 21 and 24 months

  4. Bone remodelling and modelling assessed using bone histology (jamshidi biopsy)

    Investigate the activation of bone remodelling and modelling-based bone formation by ROMO assessed by bone histology (jamshidi biopsy) at 1 (any group), 6 (any group), 18 (group 3), 19 (group 2) and 24 (group 2) months. Biopsies will be obtained from 15 participants at each timepoint. Investigate the depletion of osteoprogenitor cells during ROMO treatment assessed by molecular bone histology and single-nucleic transcriptomics.

    Time frame: Month 1, 6, 18, 19, 24

  5. Investigate the number and composition of osteoprogenitor cells in the bone marrow during the first and second romosozumab treatment.

    Investigate the number and composition of osteoprogenitor cells in the bone marrow during the first and second romosozumab treatment. Bone marrow (BM) aspirates will be obtained by aspiration of the iliac crest (10-15 ml) during the jamshidi biopsy.

    Time frame: Month 1 and 19

  6. Effect of romosozumab on glucose metabolism and insulin sensitivity (measurement of fasting glucose)

    Change in fasting glucose (mmol/l) Blood sample

    Time frame: Month 1 and 3

  7. Effect of romosozumab on glucose metabolism and insulin sensitivity (measurement of Hba1c)

    Change in glycated haemoglobin (Hba1c) (mmol/mol) Blood sample

    Time frame: Month 1 and 3

  8. Effect of romosozumab on glucose metabolism and insulin sensitivity (ogtt)

    Change in oral Glucose tolerance test (OGTT) Data is collected by giving glucose and blood samples are taken afterward to determine the patients blood sugar (mmol/l) how quickly it is cleared from the blood

    Time frame: Month 1 and 3

  9. Effect of romosozumab on glucose metabolism and insulin sensitivity (HOMA-IR)

    Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) calculated from fasting blood sugar (blood sample) and insulin levels (blood sample) by following equation: (\[insulin (μU/ml)\] × \[fasting glucose (mmol/l)\]/22,5)

    Time frame: Month 1 and 3

07

Study locations

1 of 1 sites recruiting
  • Department of Endrocinology and Internal Medicine
    Aarhus, 8000, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Aug 2030, 82 months after the start.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 82 months is above that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 28, 2023
StartActual
Oct 2, 2023
Primary completionEst.
Aug 31, 2030
CompletionEst.
Aug 31, 2032
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059222
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Oct 2, 2023
Primary completion
Aug 31, 2030 (estimated)
Completion
Aug 31, 2032 (estimated)
Last update
Jul 2, 2026

Study contacts

Vivi Makinen, MD
Contact
vivmaa@rm.dk
78450000
Bente Langdahl, MD, Professor, DMSc, PhD,
study director · Department of Endocrinology and Internal medicin, Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Romosozumab · Zoledronic Acid

Start the discussion